Billing and Coding: MolDX: Oncotype DX® Breast Cancer Assay

The Oncotype DX Breast assay is intended for ER-positive invasive breast carcinoma in patients who are node-negative, have micrometastases, or have 1–3 positive nodes. Billing requires CPT 81519, Days/Unit = 1, the appropriate ICD-10-CM diagnosis code, and the DEX Z-Code identifier placed adjacent to the CPT code in specified claim fields; DCIS (Oncotype DX DCIS) is a separate test and must not be submitted with the same Z-Code.

"Oncotype DX Breast is indicated for estrogen-receptor (ER) positive, node-negative invasive carcinoma of the breast."

Sign up to see full coverage criteria, indications, and limitations.